9PT.MU
Healthcare BiotechnologyPliant Therapeutics, Inc.
€0.92
-0.02 -2.55% today
Price History
Not enough data
Key Stats
Market Cap
56.78M
Avg Volume
18
EPS
-€1.29
52W High
€1.56
52W Low
€0.92
Div. Yield
0.0%
Valuation
P/B Ratio
0.43
EV/EBITDA
0.76
Margins
Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
EBITDA Margin 0.0%
Growth & Returns
Return on Equity
(50.3%)
Return on Assets
(23.3%)
Liquidity & Leverage
Current Ratio
9.90
Quick Ratio
9.64
Debt / Equity
0.20
Total Cash
158.10M
Total Debt
28.74M
About
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
pliantrx.com